Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: - | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Based on a GLP compliant acute oral toxicity study (OECD 423), the oral LD50 of the test material in rats is > 2000 mg/kg bw.
No acute toxicity study for dermal toxicity is available for the substance itself. However, at the moment information on acute dermal toxicity is derived from analogues. In these studies no signs of acute toxicity were observed.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- January 21 - February 18, 2021
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Version / remarks:
- December 17, 2001
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- LUBW Landesanstalt für Umwelt Baden-Württemberg, Griesbachstraße 1, 76185 Karlsruhe
- Test type:
- acute toxic class method
- Limit test:
- yes
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Batch number of test material: 0019913739
- Test item No.: 12/0028-3
- Expiry date: November 01, 2021
- Purity: ~ 96%; Mn=760 g/mol; Mw: 990 g/mol; D = Mw/Mn = 1.3; For details see GLP-characterization No. 20L00189
- Physical state / color: Liquid, viscous / yellowish, clear
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: Room temperature
- Homogeneity: The test item was homogeneous by visual inspection.
- Storage stability: The stability of the test item under storage conditions over the study period was guaranteed by the sponsor, and the sponsor holds this responsibility.
- Analysis of feed: The feed used in the study was assayed for chemical and microbial contaminants by the manufacturer in regular intervals (several times a year). Results are archived by Bioassay.
- Analysis of drinking water: The drinking water was regularly assayed for contaminants by the municipal authorities of Heidelberg. The German Drinking Water Regulation of Dec. 5, 1990 served as the guideline for maximum tolerable contaminants.
- Bedding and enrichment analysis: The bedding and enrichment were regularly assayed for contaminants (chlorinated hydrocarbons and heavy metals).
FORM AS APPLIED IN THE TEST
- Test item homogenization until the end of each administration period:
The homogeneity of the test item during administration was ensured by stirring with a magnetic stirrer.
- Form of administration: Undiluted
OTHER SPECIFICS
- Density [g/mL]: 0.984 (determined by Bioassay Laboratories) - Species:
- rat
- Strain:
- Wistar
- Remarks:
- Crl:WI (Han) SPF
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Wiga GmbH, Germany
- Females nulliparous and non-pregnant: yes
- Age at study initiation: Young adult animals (female animals approx. 10-11 weeks)
- Weight at study initiation: Animals of comparable weight (± 20% of the mean weight, actual weights see Table 5)
- Housing: Makrolon cage, type III; Single housing
- Fasting period: Feed was withdrawn from the animals at least 16 hours before administration, but water was available ad libitum.
- Diet: ad libitum; LASQCdiet® Rod16, HiHyg, LASvendi (Altromin, 32791 Lage, Germany)
- Water: ad libitum; Tap water
- Bedding: H 15005-29; Ssniff, Spezialdiäten GmbH (Experimental Animal Diets Inc., 59494 Soest, Germany)
- Enrichment: Wooden gnawing blocks (Type NGM E-022); ABEDD® LAB & VET Service GmbH, Hasnerstraße 84/6; 1160 Wien – Austria
- Acclimation period: At least 5 days before the beginning of the experimental phase; during the acclimatization period, the animals were accustomed to the environmental conditions of the study and to the diet.
- Identification: Individual identification by cage cards and tail marking.
ENVIRONMENTAL CONDITIONS
- Temperature: 22°C +/- 3°C
- Humidity: 30 – 70 %
- Air changes (per hr): Approx. 10
- Photoperiod (hrs dark/hrs light): 12h/12h (6.00a.m. – 6.00p.m./ 6.00p.m.–6.00a.m.) - Route of administration:
- oral: gavage
- Vehicle:
- unchanged (no vehicle)
- Doses:
- 2000 mg/kg bw
- No. of animals per sex per dose:
- 3 (see table 1)
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Time of day of administration: In the morning
- Frequency of weighing: Individual body weights shortly before administration (day 0), weekly thereafter and on the last day of observation.
- Clinical observations: Clinical signs for each animal were recorded several times on the day of administration and at least once during each workday thereafter.
- Mortality: A check for any dead or moribund animals was made at least once each workday.
- Necropsy of survivors performed: yes; Necropsy with gross-pathology examination was performed on the last day of the observation period after sacrifice by CO2-inhalation in a chamber with gradually increasing concentrations. - Statistics:
- Calculations were performed using Microsoft Excel 2010 and checked with a calculator.
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Remarks on result:
- other: no mortality occured
- Mortality:
- No mortality occurred in both test groups dosed with 2000 mg/kg bw.
- Clinical signs:
- other: In the first 2000 mg/kg bw. test group impaired general state and piloerection were observed in all animals from hour 1 or 2 until hour 5, while diarrhea was seen in two of these animals at hour 3 or from hour 2 until hour 4. In addition, dyspnoea and cow
- Gross pathology:
- There were no macroscopic pathological findings in any animal sacrificed at the end of the observation period.
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- Under the conditions of this study the median lethal dose of the test substance after oral administration was assessed to be greater than 2000 mg/kg bw in rats.
- Executive summary:
In an acute oral toxicity study performed according to the Acute Toxic Class Method, a dose of 2000 mg/kg bw of the undiluted test item was administered by gavage to two test groups of three fasted Wistar rats each (6 females).
The following test substance-related clinical observations were recorded, clinical signs occurred within the first 5 hours after administration:2000 mg/kg (first test group):
- No mortality occurred
- Impaired general state in all animals
- Dyspnoea in one animal
- Piloerection in all animals
- Diarrhea in two animals
- Cowering position in one animal2000 mg/kg (second test group):
- No mortality occurred
- Impaired general state in two animals
- Piloerection in two animals
- Diarrhea in two animalsAll animals gained weight in a normal range throughout the study period.
There were no macroscopic pathological findings in any animal sacrificed at the end of the observation period (6 females).
The acute oral LD50 was assessed to be LD50, oral, rat > 2000 mg/kg bw
Reference
Table 2: MORTALITY
Mortality | ||
Dose (mg/kg bw): | 2000 | 2000 |
Sex: | female | female |
Administration: | 1 | 2 |
No. of animals: | 3 | 3 |
Mortality (animals): | No mortality | No mortality |
Table 3: MAXIMUM INCIDENCE OF CLINICAL SIGNS I
Dose (mg/kg bw): | 2000 | ||
Sex: | female | ||
Administration: | 1 | ||
No. of animals: | 3 | ||
Animal No.: | R 142 | R 143 | R 144 |
Abnormalities: | |||
Impaired general state: | h2 - h5 | h1 - h5 | h2 - h5 |
Dyspnoea: | - | h3 - h4 | - |
Piloerection: | h2 - h5 | h1 - h5 | h2 - h5 |
Diarrhea: | - | h3 | h2 - h4 |
Cowering position: | - | h3 - h4 | - |
Table 4: MAXIMUM INCIDENCE OF CLINICAL SIGNS II
Dose (mg/kg bw): | 2000 | ||
Sex: | female | ||
Administration: | 2 | ||
No. of animals: | 3 | ||
Animal No.: | R 148 | R 149 | R 150 |
Abnormalities: | |||
Impaired general state: | - | h3 - h4 | h3 - h4 |
Piloerection: | - | h3 - h4 | h3 - h4 |
Diarrhea: | - | h3 | h3 |
Table 5: BODY WEIGHTS
Individual body weight changes | ||||||||||
Dose (mg/kg bw): | 2000 | 2000 | ||||||||
Administration: | 1 | 2 | ||||||||
Animal No.: | R | R | R | Mean weight | Standard- deviation | R | R | R | Mean weight | Standard- deviation |
142 | 143 | 144 | 148 | 149 | 150 | |||||
Body weight at study day (g): | ||||||||||
0 | 194 | 192 | 196 | 194.0 | 2.00 | 188 | 184 | 190 | 187.3 | 3.06 |
7 | 219 | 202 | 216 | 212.3 | 9.07 | 208 | 206 | 210 | 208.0 | 2.00 |
14 | 228 | 204 | 223 | 218.3 | 12.66 | 219 | 216 | 220 | 218.3 | 2.08 |
Table 6: GROSS PATHOLOGY
Gross Pathology | ||||||
Dose (mg/kg bw): | 2000 | 2000 | ||||
Administration: | 1 | 2 | ||||
No. of animals: | 3 | 3 | ||||
Animal No.: | R 142 | R 143 | R 144 | R 148 | R 149 | R 150 |
Macroscopic pathologic abnormalities: | - | - | - | - | - | - |
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- discriminating dose
- Value:
- 2 000 mg/kg bw
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- discriminating dose
- Value:
- 2 000 mg/kg bw
Additional information
Acute oral toxicity
In an acute oral toxicity study performed according to the Acute Toxic Class Method, a dose of 2000 mg/kg bw of the undiluted test substance was administered by gavage to two test groups of three fasted Wistar rats each (6 females).
The following test substance-related clinical observations were recorded, clinical signs occurred within the first 5 hours after administration:
2000 mg/kg (first test group):
- No mortality occurred
- Impaired general state in all animals
- Dyspnoea in one animal
- Piloerection in all animals
- Diarrhea in two animals
- Cowering position in one animal
2000 mg/kg (second test group):
- No mortality occurred
- Impaired general state in two animals
- Piloerection in two animals
- Diarrhea in two animals
All animals gained weight in a normal range throughout the study period.
There were no macroscopic pathological findings in any animal sacrificed at the end of the observation period (6 females).
The acute oral LD50 was assessed to be LD50, oral, rat > 2000 mg/kg bw (BASF, 2021)
Conclusion acute oral toxicity:
Under the conditions of this study the median lethal dose of the test substance after oral administration was assessed to be greater than 2000 mg/kg bw in rats.
Acute dermal toxicity
No acute toxicity study for dermal toxicity is available for the substance itself. However, at the moment information on acute dermal toxicity is derived from analogues. In these studies no signs of acute toxicity were observed.
Acute dermal toxicity (CAS 85586-35-2):
The substance was tested in an acute dermal toxicity test in 5 male and 5 female rats according to OECD guideline 402. No treatment-related effects were observed at the dose level of 5000 mg/kg bw. The acute dermal LD50 was determined to be higher than 5000 mg/kg bw (Bioassay, 2013).
Acute dermal toxicity (CAS 151551-88-0)
The test item was subjected to an acute dermal toxicity study according to EU method B.3 cited as Directive 79/831/EWG, Annex V, Part B in Wistar rats. No treatment related effects were observed at dose level of 2000 mg/kg bw. The acute dermal discriminating dose-value was determined to be 2000 mg/kg bw (Henkel 1989).
Acute dermal toxicity (Oleic methyl ester, epoxidized, reaction products with glycerol):
The test substance was tested in an acute dermal toxicity study according to EU method B.3 cited as Directive 79/831/EWG, Annex V, Part B in Sprague Dawley rats. No treatment related effects were observed at a dose levels of 2000 mg/kg bw. The acute dermal discriminating dose-value was determined to be 2000 mg/kg bw (Henkel 1985).
Conclusion acute dermal toxicity: No lethality is observed in the available studies performed with structural analogues. The LD50 of 2000 mg/kg bw is adapted for the substance as a conservative value in this weight-of-evidence.
Justification for classification or non-classification
Based on the available data no classification and labeling is warranted for acute toxicity in accordance with EU Classification, Labeling and Packaging of Substances and Mixtures (CLP) Regulation No. 1272/2008
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.